The effect of pulmonary artery catheter use on costs and long-term outcomes of acute lung injury
Gilles Clermont, Lan Kong, Lisa A Weissfeld, Judith R Lave, Gordon D Rubenfeld, Mark S Roberts, Alfred F Connors Jr, Gordon R Bernard, B Taylor Thompson, Arthur P Wheeler, Derek C Angus, NHLBI ARDS Clinical Trials Network, Gilles Clermont, Lan Kong, Lisa A Weissfeld, Judith R Lave, Gordon D Rubenfeld, Mark S Roberts, Alfred F Connors Jr, Gordon R Bernard, B Taylor Thompson, Arthur P Wheeler, Derek C Angus, NHLBI ARDS Clinical Trials Network
Abstract
Background: The pulmonary artery catheter (PAC) remains widely used in acute lung injury (ALI) despite known complications and little evidence of improved short-term mortality. Concurrent with NHLBI ARDS Clinical Trials Network Fluid and Catheters Treatment Trial (FACTT), we conducted a prospectively-defined comparison of healthcare costs and long-term outcomes for care with a PAC vs. central venous catheter (CVC). We explored if use of the PAC in ALI is justified by a beneficial cost-effectiveness profile.
Methods: We obtained detailed bills for the initial hospitalization. We interviewed survivors using the Health Utilities Index Mark 2 questionnaire at 2, 6, 9 and 12 m to determine quality of life (QOL) and post-discharge resource use. Outcomes beyond 12 m were estimated from federal databases. Incremental costs and outcomes were generated using MonteCarlo simulation.
Results: Of 1001 subjects enrolled in FACTT, 774 (86%) were eligible for long-term follow-up and 655 (85%) consented. Hospital costs were similar for the PAC and CVC groups ($96.8k vs. $89.2k, p = 0.38). Post-discharge to 12 m costs were higher for PAC subjects ($61.1k vs. 45.4k, p = 0.03). One-year mortality and QOL among survivors were similar in PAC and CVC groups (mortality: 35.6% vs. 31.9%, p = 0.33; QOL [scale: 0-1]: 0.61 vs. 0.66, p = 0.49). MonteCarlo simulation showed PAC use had a 75.2% probability of being more expensive and less effective (mean cost increase of $14.4k and mean loss of 0.3 quality-adjusted life years (QALYs)) and a 94.2% probability of being higher than the $100k/QALY willingness-to-pay threshold.
Conclusion: PAC use increased costs with no patient benefit and thus appears unjustified for routine use in ALI.
Trial registration: www.clinicaltrials.gov NCT00234767.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Wheeler AP, Bernard GR, Thompson BT, Schoenfeld D, Wiedemann HP, et al. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med. 2006;354:2213–2224.
- Harvey S, Harrison DA, Singer M, Ashcroft J, Jones CM, et al. Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial. Lancet. 2005;366:472–477.
- Richard C, Warszawski J, Anguel N, Deye N, Combes A, et al. Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome: a randomized controlled trial. JAMA. 2003;290:2713–2720.
- Sandham JD, Hull RD, Brant RF, Knox L, Pineo GF, et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med. 2003;348:5–14.
- Wiener RS, Welch HG. Trends in the use of the pulmonary artery catheter in the United States, 1993-2004. JAMA. 2007;298:423–429.
- Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. NEJM. 2003;348:683–693.
- Cheung AM, Tansey CM, Tomlinson G, Diaz-Granados N, Matte A, et al. Two-year outcomes, health care use, and costs of survivors of acute respiratory distress syndrome. Am J Respir Crit Care Med. 2006;174:538–544.
- Angus DC, Clermont G, Linde-Zwirble WT, Musthafa AA, Dremsizov TT, et al. Crit Care Med [October 23 Epub ahead of print]; 2006. Healthcare costs and long-term outcomes after acute respiratory distress syndrome: A phase III trial of inhaled nitric oxide*.
- Herridge MS, Angus DC. Acute lung injury--affecting many lives. N Engl J Med. 2005;353:1736–1738.
- Angus DC, Rubenfeld GD, Roberts MS, Curtis JR, Connors AF, et al. Understanding costs and cost-effectiveness in critical care: report from the second American Thoracic Society workshop on outcomes research. Am J Respir Crit Care Med. 2002;165:540–550.
- Feeny D, Furlong W, Boyle M, Torrance GW. Multi-attribute health status classification systems. Health Utilities Index. PharmacoEconomics. 1995;7:490–502.
- Rothman ML, Hedrick SC, Bulcroft KA, Hickam DH, Rubenstein LZ. The validity of proxy-generated scores as measures of patient health status. Med Care. 1991;29:115–124.
- Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1172–1177.
- Angus DC, Musthafa AA, Clermont G, Griffin MF, Linde-Zwirble WT, et al. Quality-adjusted survival in the first year after the acute respiratory distress syndrome. Am J Respir Crit Care Med. 2001;163:1389–1394.
- Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB for the Panel on Cost-Effectiveness in Health and Medicine. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1253–1258.
- Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1992;146:473–481.
- Rubenfeld GD, Herridge MS. Epidemiology and outcomes of acute lung injury. Chest. 2007;131:554–562.
- Harvey S, Harrison DA, Singer M, Ashcroft J, Jones CM, et al. Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial. Lancet. 2005;366:472–477.
- Hindorff LA, Rice KM, Lange LA, Diehr P, Halder I, et al. Common variants in the CRP gene in relation to longevity and cause-specific mortality in older adults: the Cardiovascular Health Study. Atherosclerosis. 2008;197:922–930.
- Yende S, D'angelo G, Kellum JA, Weissfeld L, Fine J, et al. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med. 2008;177:1242–1247.
- Reade MC, Yende S, D'angelo G, Kong L, Kellum JA, et al. Differences in immune response may explain lower survival among older men with pneumonia. Crit Care Med. 2009;37:1655–1662.
- Skolarus LE, Sanchez BN, Morgenstern LB, Garcia NM, Smith MA, et al. Stroke; 2010. Validity of Proxies and Correction for Proxy Use When Evaluating Social Determinants of Health in Stroke Patients.
- Braithwaite RS, Meltzer DO, King JT, Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008;46:349–356.
- Angus D, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med. 2003;31:1–11.
Source: PubMed